Inventor
BROOKINGS DANIEL CHRISTOPHER
GB38 patents
⚠️ This page may combine multiple inventors who share the name “BROOKINGS DANIEL CHRISTOPHER”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
UCB BIOPHARMA SPRL
13 patentsUS9873703B2Jan 23, 2018
Imidazopyridazine derivatives as modulators of TNF activity
UCB BIOPHARMA SPRL8 citations83
US9868749B2Jan 16, 2018
Fused imidazole and pyrazole derivatives as modulators of TNF activity
UCB BIOPHARMA SPRL16 citations81
US9550737B2Jan 24, 2017
TNF -α modulating benzimidazoles
UCB BIOPHARMA SPRL4 citations71
US10202405B2Feb 12, 2019
Fused pentacyclic imidazole derivatives
UCB BIOPHARMA SPRL4 citations70
US9475820B2Oct 25, 2016
Substituted imidazo[1,2-a]pyrazines as TNF activity modulators
UCB BIOPHARMA SPRL3 citations70
US9309243B2Apr 12, 2016
Imidazopyridine derivatives as modulators of TNF activity
UCB BIOPHARMA SPRL4 citations68
US10053464B2Aug 21, 2018
Triazolopyridazine derivatives as modulators of TNF activity
UCB BIOPHARMA SPRL1 citations52
US9957255B2May 1, 2018
Benzotriazole derivatives as modulators of TNF activity
UCB BIOPHARMA SPRL1 citations52
US9902720B2Feb 27, 2018
Pyrazolopyridine derivatives as modulators of TNF activity
UCB BIOPHARMA SPRL1 citations52
US9850240B2Dec 26, 2017
Triazolopyridine derivatives as modulators of TNF activity
UCB BIOPHARMA SPRL1 citations52
US9932342B2Apr 3, 2018
Imidazopyrimidine derivatives as modulators of TNF activity
UCB BIOPHARMA SPRL1 citations51
US9714251B2Jul 25, 2017
Imidazotriazine derivatives as modulators of TNF activity
UCB BIOPHARMA SPRL1 citations51
US9382263B2Jul 5, 2016
Therapeutically active oxazoline derivatives
UCB BIOPHARMA SPRL0 citations38
UCB PHARMA SA
8 patentsUS7592455B2Sep 22, 2009
Bicyclic heteroaromatic compounds as kinase inhibitors
UCB PHARMA SA16 citations84
US7521460B2Apr 21, 2009
Thienopyridone derivatives as kinase inhibitors
UCB PHARMA SA17 citations84
US7763729B2Jul 27, 2010
Bicyclic heteroaromatic derivatives
UCB PHARMA SA2 citations62
US9096614B2Aug 4, 2015
Therapeutically active thiazolo-pyrimidine derivatives
UCB PHARMA SA2 citations60
US7888344B2Feb 15, 2011
Fused thiazole derivatives as kinase inhibitors
UCB PHARMA SA3 citations58
US8604051B2Dec 10, 2013
Thieno-pyridine derivatives as MEK inhibitors
UCB PHARMA SA1 citations51
US8350037B2Jan 8, 2013
Thieno-pyridine derivatives as MEK inhibitors
UCB PHARMA SA1 citations51
US7456286B2Nov 25, 2008
Bicyclic heteroaromatic compounds as kinase inhibitors
UCB PHARMA SA1 citations49
UCB Biopharma SRL
6 patentsUS10883996B2Jan 5, 2021
Methods of identifying signaling modulators of the trimeric TNFa
UCB Biopharma SRL7 citations83
US10906919B2Feb 2, 2021
Fused pentacyclic imidazole derivatives
UCB Biopharma SRL2 citations70
US11912721B2Feb 27, 2024
Fused pentacyclic imidazole derivatives
UCB Biopharma SRL0 citations60
US10980814B2Apr 20, 2021
Fused pentacyclic imidazole derivatives as modulators of TNF activity
UCB Biopharma SRL0 citations60
US10953019B2Mar 23, 2021
Fused pentacyclic imidazole derivatives as modulators of TNF activity
UCB Biopharma SRL0 citations51
US11458124B2Oct 4, 2022
Spirocyclic indane analogues as IL-17 modulators
UCB Biopharma SRL0 citations48
CELLTECH R&D LTD
3 patentsUS7423047B2Sep 9, 2008
Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors
CELLTECH R&D LTD8 citations73
US7176215B2Feb 13, 2007
Bicyclic oxopyridine and oxopyrimidine derivatives
CELLTECH R&D LTD3 citations62
US7323464B2Jan 29, 2008
Pyridine and pyrimidine derivatives
CELLTECH R&D LTD3 citations58